Aquaculture Disease Management: Welfare and Antibiotic Use

Disease management in aquaculture involves trade-offs between treatment welfare, antibiotic resistance, and preventive approaches. Understanding the welfare dimensions helps drive more sustainable practices.

Key Facts

Salmon aquaculture uses significant quantities of antibiotics globally, though use has fallen sharply in Norway and Scotland
Norwegian salmon aquaculture reduced antibiotic use by 98% between 1987 and 2012 through vaccination programmes
Bacterial diseases including furunculosis and bacterial kidney disease affect welfare through ulcers, organ damage and mortality
Handling fish to treat disease causes acute stress that may exacerbate welfare outcomes
In-feed medication avoids handling stress but requires the ability to target individual affected fish
Vaccines administered by injection in smolts provide long-term protection - a major welfare improvement over repeated treatments
Antimicrobial resistance emerging from aquaculture threatens both fish welfare and human health

Welfare Considerations

Disease in farmed fish causes welfare harm through the disease process itself - ulcers, organ damage, and systemic infection cause pain and distress - and through the treatment process, which typically requires handling and bathing procedures that add further stress. The Norwegian success in dramatically reducing antibiotic use through vaccination demonstrates that preventive approaches can simultaneously improve individual fish welfare (avoiding disease) and reduce antibiotic resistance risks. Prevention-first disease management is both a welfare and a public health priority.

What You Can Do

Choose farmed salmon from countries with documented low antibiotic use standards, particularly Norway and Scotland
Support certification schemes that include antibiotic stewardship criteria in aquaculture welfare standards
Advocate for mandatory reporting of aquaculture antibiotic use in countries where data is not publicly available
Reduce farmed fish consumption to lower demand pressure on intensive systems with higher disease burdens